Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has announced the successful development of a clinical-grade assay to assess FLT3 protein expression in acute myeloid leukemia (AML) cells. This assay is important for identifying and recruiting patients for the upcoming Phase I clinical trials of the company's HEMO-CAR-T product candidate. The trials are set to begin shortly at MD Anderson Cancer Center, with plans to expand to the University of Pennsylvania Medical Center.
The development of this assay marks a significant milestone in advancing HEMO-CAR-T towards clinical trials, potentially offering a life-saving treatment for AML patients. Dr. Vladislav Sandler, CEO and Co-Founder of Hemogenyx, expressed excitement about the imminent start of Phase I trials at MD Anderson, a leading institution in cancer care.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) ha annunciato lo sviluppo con successo di un saggio di grado clinico per valutare l'espressione della proteina FLT3 nelle cellule della leucemia mieloide acuta (LMA). Questo saggio è importante per identificare e reclutare pazienti per i futuri trial clinici di Fase I del candidato prodotto HEMO-CAR-T dell'azienda. I trial inizieranno a breve presso il MD Anderson Cancer Center, con piani di espansione al University of Pennsylvania Medical Center.
Lo sviluppo di questo saggio rappresenta una pietra miliare significativa per portare HEMO-CAR-T verso i trial clinici, offrendo potenzialmente un trattamento salvavita per i pazienti affetti da LMA. Il Dr. Vladislav Sandler, CEO e Co-fondatore di Hemogenyx, ha espresso entusiasmo per l'imminente avvio dei trial di Fase I al MD Anderson, una delle principali istituzioni nella cura del cancro.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) ha anunciado el desarrollo exitoso de un ensayo de grado clínico para evaluar la expresión de la proteína FLT3 en células de leucemia mieloide aguda (LMA). Este ensayo es importante para identificar y reclutar pacientes para los próximos ensayos clínicos de Fase I del candidato a producto HEMO-CAR-T de la empresa. Los ensayos comenzarán en breve en el MD Anderson Cancer Center, con planes de expandirse al University of Pennsylvania Medical Center.
El desarrollo de este ensayo marca un hito significativo en el avance de HEMO-CAR-T hacia los ensayos clínicos, ofreciendo potencialmente un tratamiento que salva vidas para los pacientes con LMA. El Dr. Vladislav Sandler, CEO y cofundador de Hemogenyx, expresó su entusiasmo por el inminente inicio de los ensayos de Fase I en MD Anderson, una institución líder en el cuidado del cáncer.
Hemogenyx Pharmaceuticals plc (LSE:HEMO)는 급성 골수성 백혈병(AML) 세포에서 FLT3 단백질 발현을 평가하기 위한 임상용 분석법의 성공적인 개발을 발표했습니다. 이 분석법은 회사의 HEMO-CAR-T 제품 후보의 다가오는 1상 임상 시험을 위해 환자를 식별하고 모집하는 데 중요합니다. 시험은 곧 MD Anderson Cancer Center에서 시작될 예정이며, 펜실베이니아 대학 의료센터로 확대할 계획입니다.
이 분석법의 개발은 HEMO-CAR-T를 임상 시험으로 진행하는 데 있어 중요한 이정표로, AML 환자에게 생명을 구하는 치료법을 제공할 가능성을 보여줍니다. Hemogenyx의 CEO이자 공동 창립자인 블라디슬라프 샌들러 박사는 MD Anderson에서 1상 시험이 곧 시작될 것에 대해 기대감을 표명했습니다. MD Anderson은 암 치료 분야의 선도 기관입니다.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) a annoncé le développement réussi d'un essai de qualité clinique pour évaluer l'expression de la protéine FLT3 dans les cellules de leucémie myéloïde aiguë (LMA). Cet essai est important pour identifier et recruter des patients pour les futurs essais cliniques de Phase I du candidat produit HEMO-CAR-T de l'entreprise. Les essais devraient commencer prochainement au MD Anderson Cancer Center, avec des plans d'expansion vers le University of Pennsylvania Medical Center.
Le développement de cet essai marque une étape significative dans l'avancement de HEMO-CAR-T vers les essais cliniques, offrant potentiellement un traitement salvateur pour les patients atteints de LMA. Dr. Vladislav Sandler, PDG et co-fondateur de Hemogenyx, a exprimé son enthousiasme concernant le début imminent des essais de Phase I au MD Anderson, une institution de premier plan en matière de soins contre le cancer.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) hat die erfolgreiche Entwicklung eines klinischen Assays zur Bewertung der FLT3-Proteinexpression in Zellen der akuten myeloischen Leukämie (AML) bekannt gegeben. Dieses Assay ist wichtig für die Identifizierung und Rekrutierung von Patienten für die bevorstehenden Phase-I-Klinikversuche des Produktkandidaten HEMO-CAR-T des Unternehmens. Die Versuche sollen bald im MD Anderson Cancer Center beginnen, mit dem Plan, auf das University of Pennsylvania Medical Center auszudehnen.
Die Entwicklung dieses Assays stellt einen bedeutenden Meilenstein dar, um HEMO-CAR-T in Richtung klinischer Tests voranzubringen, möglicherweise ein lebensrettendes Behandlung für AML-Patienten bietend. Dr. Vladislav Sandler, CEO und Mitbegründer von Hemogenyx, äußerte seine Begeisterung über den bevorstehenden Beginn der Phase-I-Studien am MD Anderson, einer führenden Institution in der Krebsversorgung.
- Successful development of a clinical-grade FLT3 assay for patient selection
- Imminent start of Phase I clinical trials for HEMO-CAR-T at MD Anderson Cancer Center
- Planned expansion of trials to the University of Pennsylvania Medical Center
- None.
LONDON, UNITED KINGDOM / ACCESSWIRE / September 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, is pleased to announce the successful completion of the development of a clinical-grade assay ("Assay") designed to assess FLT3 protein expression in acute myeloid leukemia ("AML") cells.
Assessing FLT3 protein expression in AML cells is crucial for the accurate identification and recruitment of patients for the imminent Phase I clinical trials of the Company's HEMO-CAR-T product candidate. The trials are expected to commence shortly at MD Anderson Cancer Center ("MD Anderson"), one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. The Phase I clinical trials are planned to expand to the University of Pennsylvania Medical Center thereafter.
Dr Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals, commented:
"The completion of our FLT3 assay marks a critical milestone in advancing our HEMO-CAR-T product candidate into clinical trials. This Assay will ensure we can accurately identify and recruit the right patients for the trials, bringing us one step closer to providing a potentially life-saving treatment for those battling AML. We are excited to begin our Phase I trials imminently at MD Anderson Cancer Center, a leading institution in cancer care, and look forward to expanding our efforts to the University of Pennsylvania Medical Center."
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
About AML
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than
About ALL
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that primarily affects children, although it can also occur in adults. Unlike Acute Myeloid Leukemia (AML), ALL is characterized by the rapid proliferation of immature lymphocytes, a type of white blood cell. ALL is the most common childhood cancer, representing approximately
About MD Anderson
The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. The mission of the MD Anderson is to eliminate cancer in Texas, the USA, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
What is the significance of Hemogenyx's new FLT3 assay for AML treatment?
When and where will Hemogenyx (HOPHF) begin Phase I trials for HEMO-CAR-T?
What is the potential impact of Hemogenyx's HEMO-CAR-T product for AML patients?
How does the new FLT3 assay contribute to Hemogenyx's (HOPHF) clinical trial process?
